Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 6/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | RARB | P10826 | 4/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | RARA | P10276 | 1/20 | 0.34 |
| ▸ | RARG | P13631 | 1/20 | 0.34 |
| ▸ | LPL | P06858 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1249598 | 0.84 | MPL (0.39) | MPLCNR2CNR1ALOX5RARB | |
| SCHEMBL1249596 | 0.81 | FGFR2 (0.39) | MPLALOX5RARBGABRA1GABRB2 | |
| SCHEMBL17356675 | 0.81 | RARB (0.38) | MPLCNR2CNR1ALOX5RARB | |
| SCHEMBL17356678 | 0.81 | RARB (0.38) | MPLCNR2CNR1ALOX5RARB | |
| SCHEMBL3272921 | 0.81 | CNR1 (0.50) | MPLCNR2CNR1ALOX5RARB | |
| SCHEMBL1249361 | 0.80 | RARB (0.40) | MPLCNR2CNR1ALOX5RARB | |
| SCHEMBL13289835 | 0.79 | MPL (0.48) | MPLALOX5RARBMCL1RARA | |
| SCHEMBL19824580 | 0.79 | MCL1 (0.49) | MPLCNR2CNR1ALOX5RARB | |
| SCHEMBL17487571 | 0.78 | RARB (0.36) | MPLALOX5RARBRARARARG | |
| SCHEMBL12189903 | 0.77 | CNR1 (0.41) | MPLCNR2CNR1ALOX5RARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1544187-B1 | 1,7,8-TRIFLUORONAPHTHALENE-2-NAPHTHOL, AND METHODS FOR PRODUCING LIQUID CRYSTAL COMPOUNDS USING SAME | DAINIPPON INK & CHEMICALS (JP) | 2011-02-16 | — | — | EP | disclosed |
| US-7214835-B2 | 1,7,8-Trifluoronaphthalene-2-naphthol, and method for producing liquid crystal compound using same | DAINIPPON INK & CHEMICALS, INC. (JP) | 2007-05-08 | — | — | US | disclosed |
| US-7214835-B2 | 1,7,8-Trifluoronaphthalene-2-naphthol, and method for producing liquid crystal compound using same | DAINIPPON INK & CHEMICALS, INC. (JP) | 2007-05-08 | — | — | US | disclosed |
| US-20060163537-A1 | 1,7,8-Trifluoronaphthalene-2-naphthol, and method for producing liquid crystal compound using same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1544187-A1 | 1,7,8-TRIFLUORONAPHTHALENE-2-NAPHTHOL, AND METHOD FOR PRODUCING LIQUID CRYSTAL COMPOUND USING SAME | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2005-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060163537-A1 | 1,7,8-Trifluoronaphthalene-2-naphthol, and method for producing liquid crystal compound using same | NOC2L, SNX2, NEFM | MPL 3439/4885CNR2 2886/4885CNR1 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.